SCHEMBL6824028

SCHEMBL6824028

CCOC(=O)N1CCC(O)(C#N)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
GAA P10253 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
TSHR P16473 1/20 0.47
POLB P06746 2/20 0.46
HTT P42858 1/20 0.46
RECQL P46063 1/20 0.44
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPT P10636 2/20 0.41
ABL1 P00519 1/20 0.41
RIN1 Q13671 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
THRB P10828 1/20 0.41
ATM Q13315 1/20 0.41
LMNA P02545 1/20 0.40
APP P05067 1/20 0.39
NOS3 P29474 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1140258 0.81 ALDH1A1 (0.49) ALDH1A1GAASMN1; SMN2L3MBTL1TSHR
SCHEMBL895343 0.78 L3MBTL1 (0.55) ALDH1A1GAASMN1; SMN2L3MBTL1TSHR
SCHEMBL1973674 0.78 USP2 (0.49) ALDH1A1SMN1; SMN2TSHRRECQLMEN1
SCHEMBL15461517 0.76 ALDH1A1 (0.45) ALDH1A1GAASMN1; SMN2L3MBTL1TSHR
SCHEMBL8867607 0.76 L3MBTL1 (0.45) ALDH1A1GAASMN1; SMN2L3MBTL1TSHR
SCHEMBL21138360 0.76 TSHR (0.55) ALDH1A1GAASMN1; SMN2L3MBTL1TSHR
SCHEMBL7601879 0.76 TSHR (0.55) ALDH1A1GAASMN1; SMN2L3MBTL1TSHR
SCHEMBL4423208 0.76 ALDH1A1 (0.44) ALDH1A1GAASMN1; SMN2L3MBTL1TSHR
SCHEMBL10692712 0.75 L3MBTL1 (0.53) ALDH1A1GAASMN1; SMN2L3MBTL1TSHR
SCHEMBL9373811 0.75 L3MBTL1 (0.53) ALDH1A1GAASMN1; SMN2L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6737416-B2 THROMBOLYTIC AGENT HAVING HIGHER SAFETY MEIJI SEIKA KAISHA LTD. (JP) 2004-05-18 US disclosed
US-20030119787-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B MEIJI SEIKA KAISHA LTD. (JP) 2003-06-26 US disclosed
US-6576627-B1 Such as 7-amino-2-((2-methyl-1-(3-phenylpropanoylamino)-propyl)hydroxyphosphinoyl) -methylheptanoic acid; thrombotic disease MEIJI SEIKA KAISHA LTD. (JP) 2003-06-10 US disclosed
EP-1152004-B1 Phosphonic acid derivatives having carboxypeptidase B inhibitory action MEIJI SEIKA KAISHA (JP) 2003-05-07 EP disclosed
EP-1174434-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B MEIJI SEIKA KAISHA LTD. (JP) 2002-01-23 EP disclosed
EP-1152004-A1 PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY MEIJI SEIKA KAISHA LTD. (JP) 2001-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119787-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B CPB1, RNPEP, CPN1 ALDH1A1 1869/4885GAA 180/4885SMN1; SMN2 4505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.